Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain blood flow under the knife: remimazolam vs propofol

NCT ID NCT07303985

Knowledge-focused Sponsor: Jun Zhang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how remimazolam, a newer sedative, changes blood flow in the brain compared to the standard drug propofol during the start of anesthesia. Fifty-two adults having planned surgery took part. The goal was to measure blood flow speed in a key brain artery right after the drugs were given and after the breathing tube was placed. The results could help anesthesiologists choose the best sedative for patients where brain blood flow is a concern.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remimazolam

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

52 people

The number who actually took part.

Started

Dec 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who have signed the informed consent form and are willing to comply with the study protoco * Age greater than 18 years * ASA physical status classification I to II * Scheduled for elective surgery * Undergoing general anesthesia with endotracheal intubation * No history of cerebrovascular disease, carotid artery stenosis, or traumatic brain injury. Exclusion Criteria: * History of intracranial lesions, carotid artery stenosis, or traumatic brain injury * Allergy or contraindications to remimazolam or propofol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral blood flow are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral blood flow

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Centre

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.